scholarly journals Reply to the Comment by Dr. Cure on “Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade”

Nephron ◽  
2020 ◽  
Vol 144 (5) ◽  
pp. 253-254 ◽  
Author(s):  
Luca Perico ◽  
Ariela Benigni ◽  
Giuseppe Remuzzi
Keyword(s):  
Angiotensin Blockade

Effekte der systemischen Angiotensin-Blockade bei Patienten mit COPD. Eine randomisierte, placebokontrollierte doppeltblinde Studie

Pneumologie ◽  
2005 ◽  
Vol 59 (S 1) ◽  
Author(s):  
W Körber ◽  
L Lüthje ◽  
C Herrmann-Lingen ◽  
B Buechner ◽  
CP Criee ◽  
...  
Keyword(s):  
Angiotensin Blockade

526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 526-P
Author(s):  
FREDERIK PERSSON ◽  
MIE K. EICKHOFF ◽  
HARALD MISCHAK ◽  
MARIE FRIMODT-MOLLER ◽  
PETER ROSSING
Keyword(s):  
Type 2 Diabetes ◽  
Renin Angiotensin ◽  
Angiotensin Blockade

Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats

2011 ◽  
Vol 29 (10) ◽  
pp. 1919-1929 ◽  
Author(s):  
Toru Dejima ◽  
Kouichi Tamura ◽  
Hiromichi Wakui ◽  
Akinobu Maeda ◽  
Masato Ohsawa ◽  
...  
Keyword(s):  
Therapeutic Effect ◽  
Hypertensive Rats ◽  
Angiotensin Blockade

Sacubitril/Valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice when compared to valsartan treatment

2021 ◽  
Author(s):  
Komuraiah Myakala ◽  
Bryce Jones ◽  
Xiaoxin Wang ◽  
Moshe Levi
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Renal Protection ◽  
Diabetic Kidney ◽  
Renin Angiotensin ◽  
Kkay Mice ◽  
Neprilysin Inhibitor ◽  
Angiotensin Blockade

Although renin-angiotensin blockade has shown the beneficial outcomes in patients with diabetes, renal injury progresses in most of these patients. Therefore, there remains a need for new therapeutic targets in diabetic kidney disease. Enhancement of vasoactive peptides, such as natriuretic peptides, via neprilysin inhibition, has been a new approach. A first-in-class drug sacubitril/valsartan (Sac/Val), a combination of angiotensin II receptor blocker valsartan and neprilysin inhibitor prodrug sacubitril, has been shown more effective than renin-angiotensin blockade alone in the treatment of heart failure with reduced ejection fraction. In this study we tested the effects of Sac/Val in the diabetic kidney disease. We administered Sac/Val or valsartan to two type 2 diabetes mouse models, db/db mice or KKAy mice. After 3-month treatment, Sac/Val attenuated the progression of proteinuria, glomerulosclerosis, and podocyte loss in both models of diabetic mice. Valsartan shared the similar improvement but to a lesser degree in some parameters compared to Sac/Val. Sac/Val but not valsartan decreased the blood glucose level in KKAy mice. Sac/Val exerted renal protection through coordinated effects on anti-oxidative stress and anti-inflammation. In both diabetic models, we revealed a new mechanism to cause inflammation, self DNA activated cGAS-STING signaling, which was activated in diabetic kidneys and prevented by Sac/Val or valsartan treatment. Present data suggest that Sac/Val has sufficient therapeutical potential to counter the pathophysiological effects of diabetic kidney disease and its effectiveness could be better than valsartan alone.

Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril

1995 ◽  
Vol 269 (4) ◽  
pp. F491-F499 ◽  
Author(s):  
E. A. Burdmann ◽  
T. F. Andoh ◽  
C. C. Nast ◽  
A. Evan ◽  
B. A. Connors ◽  
...  
Keyword(s):  
Interstitial Fibrosis ◽  
Renal Scarring ◽  
Renin Angiotensin System ◽  
Plasma Renin ◽  
Tubular Dysfunction ◽  
Angiotensin System ◽  
Salt Diet ◽  
Renin Angiotensin ◽  
Dependent Model ◽  
Angiotensin Blockade

The pathogenesis of renal scarring in chronic cyclosporin nephropathy is unknown. In this study, we evaluated the effects of renin-angiotensin system blockade by enalapril and losartan in a salt-dependent model of cyclosporin-associated chronic tubulointerstitial fibrosis (TIF). Rats kept on normal or low-salt diet were given cyclosporin, cyclosporin+enalapril, cyclosporin+losartan, cyclosporin+enalapril#losartan, or vehicle for 14 and 28 days. Cyclosporin reduced glomerular filtration rate (GFR) in rats fed either diet, but only salt-depleted animals developed significant TIF. Cyclosporin also impaired renal concentrating ability and caused tubular enzymuria. Renin-angiotensin system blockade decreased blood pressure (BP) and promoted afferent arteriolar vasodilatation. Losartan reduced plasma renin activity and prevented cyclosporin-induced increment of cortical alpha 1(I) procollagen mRNA. Renin-angiotensin blockade did not improve GFR and tubular function; however, it strikingly prevented TIF development, even in presence of very low BP. Rats treated with cyclosporin, hydralazine, and furosemide achieved BP values similar to losartan or enalapril groups, but there was no protection against interstitial fibrosis development. These results suggest that cyclosporin-related chronic interstitial injury is mediated by angiotensin II and that the mechanisms promoting the interstitial scarring can be dissociated from glomerular and tubular dysfunction in cyclosporin nephropathy.

scholarly journals Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis

2017 ◽  
Vol 4 (4) ◽  
pp. 402-408 ◽  
Author(s):  
Muhammad Shahzeb Khan ◽  
Gregg C. Fonarow ◽  
Hassan Khan ◽  
Stephen J. Greene ◽  
Stefan D. Anker ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Ejection Fraction ◽  
Meta Analysis ◽  
Preserved Ejection Fraction ◽  
Renin Angiotensin ◽  
Angiotensin Blockade
Sign in / Sign up

Export Citation Format

Share Document